FORBIUS
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways, enabling doctors to have highly active inhibitors of validated pathways that have a differentiated mechanism of action. Forbius’ medicines are designed to radically transform patients’ lives. Their strength is utilizing their knowledge of biology and diverse protein engineering technologies to design superior inhibitors of validated biological pathways. Forbius was founded in 2011 as a management-led spin-out from YM BioSciences, prior to YM's acquisition by Gilead.
FORBIUS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.forbius.com
Total Employee:
11+
Status:
Active
Contact:
(164) 725-5133
Email Addresses:
[email protected]
Total Funding:
21.98 M USD
Technology used in webpage:
SPF US Privacy User Signal Mechanism WordPress 6.0 Twemoji DMARC KnowBe4 DreamHost Hosting Dreamhost DNS Cisco Ironport Cloud Dmarcian
Current Advisors List
Current Employees Featured
Founder
Investors List
HBM Partners
HBM Partners investment in Series C - Forbius
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Grant - Forbius
BioCanRx
BioCanRx investment in Grant - Forbius
Lumira Ventures
Lumira Ventures investment in Series B - Forbius
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series B - Forbius
Rosseau Asset Management
Rosseau Asset Management investment in Venture Round - Forbius
Lumira Ventures
Lumira Ventures investment in Venture Round - Forbius
MaRS Investment Accelerator Fund
MaRS Investment Accelerator Fund investment in Venture Round - Forbius
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners investment in Venture Round - Forbius
Creative Destruction Lab (CDL)
Creative Destruction Lab (CDL) investment in Series A - Forbius
Official Site Inspections
http://www.forbius.com
- Host name: 151.101.66.159
- IP address: 151.101.66.159
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Forbius"
Forbius - Crunchbase Company Profile & Funding
Forbius (Formation Biologics) is a clinical-stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The company is developing agents targeting the transforming growth factor-beta …See details»
Bristol Myers Squibb Enters Agreement to Acquire Forbius TGF …
Forbius's Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis. NEW YORK AND MONTREAL –-Bristol Myers Squibb …See details»
Bristol Myers Squibb Completes Acquisition of Forbius
Sep 21, 2020 Adds Phase 1 Isoform-Selective TGF-beta Inhibitor AVID200 to Expansive Pipeline Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully …See details»
Forbius - LinkedIn
About Forbius: Targeting EGFR and TGF-β Pathways in Cancer and Fibrosis Forbius is a clinical stage company that designs and develops biotherapeutics for the treatment of cancer and …See details»
Bristol-Myers Squibb acquires Forbius - 2020-08-24 - Crunchbase
Aug 24, 2020 Forbius Forbius is a biopharmaceutical company that develops and designs niotherapeutics for the treatment of fibrotic diseases and cancers. Acquiring Organization: …See details»
Bristol Myers Squibb Completes Acquisition of Forbius
Sep 21, 2020 NEW YORK--(BUSINESS WIRE)--Sep 21, 2020-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its transaction to acquire Forbius for …See details»
Bristol Myers Squibb Completes Acquisition of Forbius
Sep 21, 2020 Bristol Myers Squibb Completes Acquisition of Forbius Adds Phase 1 Isoform-Selective TGF-beta Inhibitor AVID200 to Expansive Pipeline September 21, 2020 04:16 PM …See details»
Forbius Company Profile 2024: Valuation, Investors, Acquisition
When was Forbius founded? Forbius was founded in 2011. Where is Forbius headquartered? Forbius is headquartered in Montreal, Canada. What is the size of Forbius? Forbius has 37 …See details»
Forbius Company Profile - Office Locations, Competitors ... - Craft
Forbius (also known as Formation Biologics) is a protein engineering company that develops biotherapeutics for the treatment of cancer and fibrotic diseases. It provides agents targeting …See details»
Forbius - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Forbius . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Forbius has 4 current employee profiles, including …See details»
Forbius - LinkedIn
Forbius | 2,273 followers on LinkedIn. A clinical stage company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. | About Forbius: Targeting …See details»
BMS swoops on Forbius, snaring another immuno-oncology player
Aug 24, 2020 Since its foundation in 2011, privately-held Forbius has been working on drugs that inhibit TGF beta 1 and 3, two targets thought to play a role in protecting cancers from …See details»
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding …
Aug 24, 2020 Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis Bristol Myers Squibb (NYSE: BMY) …See details»
Forbius Agrees to Sell to Bristol Myers Squibb - Cooley
New York – August 25, 2020 – Cooley advised Forbius – a clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic …See details»
Forbius Completes Enrollment into Phase 1a Solid Tumor Trial of …
Forbius’ lead TGF-beta 1 & 3 inhibitor, AVID200, is undergoing Phase 1 clinical trials in two fibrotic indications as well as in solid tumors. Forbius' lead program targeting EGFR is …See details»
Forbius Recognized As One of the Most Promising Life Science …
(May 31, 2016) – Forbius (Formation Biologics) was recognized as one of the Rice Alliance 10 Most Promising Life Science Companies at the 2016 Texas Life Science Forum hosted by the …See details»
Careers - Forbius
You can submit your CV to [email protected] or apply to one of the specific job postings below. We have offices in Austin and Montreal. In your application, please indicate if you are …See details»
Project Manager (Montréal) - Forbius
Job Description. Forbius is looking for an experienced Project Manager to join our energetic and high-performance team. Under the direction of the Director of Manufacturing and the …See details»
Forbius’ AVID200, a Novel TGF-beta 1 & 3 Inhibitor, Cleared by …
Austin, TX, and Montreal, QC (Apr. 29, 2019) – Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced that it has received a no …See details»